Purpose: to evaluate the safety and tolerability of a potential new drug for cystic fibrosis.
Participate in a clinical study of a potential treatment for cystic fibrosis. This is the multiple dosing portion of the study (MAD).
This study has 1 screening appointment and 13 nights/ 14 days inpatient stay and 1 follow up phone call.
Reimbursement for study participation will be provided for time and travel of up to $7,170.
This study has been reviewed by an Institutional Review Board.
Call 612-315-6490 to discuss your eligibility today!